TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
SNO Poster Nov 2022: Positive updated results from NOX-A12 Phase 1/2 GLORIA trial in GBM presented at the 2022 SNO Annual Meeting
2022, November 19
Positive updated interim results from NOX-A12 GLORIA Phase 1/2 in brain cancer presented at the Society for Neuro-Oncology 2022 Annual Meeting
2022, November 14
TME Pharma to host key opinion leader webinar
2022, November 11
TME Pharma announces publication of abstract disclosing positive interim results from bevacizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial additional and updated data to be presented during SNO 2022 Annual Meeting on Nov 18, 2022